open access
Clinical value of miR-23a-3p expression in early diagnosis of diabetic kidney disease
Affiliations- Department of Endocrinology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China
open access
Abstract
Introduction: The objective was to observe the expression of miR-23a-3p in the serum of patients with type 2 diabetic nephropathy (T2DN) and to explore its clinical significance.
Materials and methods: 112 patients with type 2 diabetes were divided into a simple diabetes mellitus (NON) group, T2DN microalbuminuria (MIC) group, and T2DN macroalbuminuria (MAC) group, according to the urinary protein-creatinine ratio (uACR). Clinical data were collected, miR-23a-3p levels in serum were measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR), and clinical parameters were measured by an automatic biochemical analyser; the influencing factors of diabetic kidney disease (DKD) and the correlation between miR-23a-3p expression and clinical parameters were analysed.
Results: The expression of miR-23a-3p in the serum of the DKD group was lower than that of the normal control (CON) and NON groups. Correlation analysis showed that miR-23a-3p was positively correlated with urinary albumin (Albu), glycosylated haemoglobin (HbA1c), total cholesterol (CHOL), glycated albumin (GA-L), serum creatinine (Scr), fasting blood glucose (GLU), and uric acid (UA), negatively correlated with uACR and high-density lipoprotein cholesterol (HDL-C), but not correlated with urinary creatinine (CREA). The area under the receiver operating characteristic (ROC) curve (AUC) of miR-23a-3p for the diagnosis of DKD was 0.686 [95% confidence interval (CI): 0.599–0.773], with a sensitivity of 64.5% and a specificity of 71.2%; the AUC for differentiating NON from DKD was 0.700 (95% CI: 0.598–0.802), with a sensitivity of 61.8% and a specificity of 77.8%. Multivariate logistic regression analysis showed that serum miR-23a-3p
levels were not associated with the development of DKD after adjusting for other levels of influence and were not significant for the differentiation of NON and DKD.
Conclusion: Serum miR-23a-3p levels are decreased in T2DN patients, and this change becomes more significant with the severity of the disease, which may be a marker for the early diagnosis and progression of T2DN.
Abstract
Introduction: The objective was to observe the expression of miR-23a-3p in the serum of patients with type 2 diabetic nephropathy (T2DN) and to explore its clinical significance.
Materials and methods: 112 patients with type 2 diabetes were divided into a simple diabetes mellitus (NON) group, T2DN microalbuminuria (MIC) group, and T2DN macroalbuminuria (MAC) group, according to the urinary protein-creatinine ratio (uACR). Clinical data were collected, miR-23a-3p levels in serum were measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR), and clinical parameters were measured by an automatic biochemical analyser; the influencing factors of diabetic kidney disease (DKD) and the correlation between miR-23a-3p expression and clinical parameters were analysed.
Results: The expression of miR-23a-3p in the serum of the DKD group was lower than that of the normal control (CON) and NON groups. Correlation analysis showed that miR-23a-3p was positively correlated with urinary albumin (Albu), glycosylated haemoglobin (HbA1c), total cholesterol (CHOL), glycated albumin (GA-L), serum creatinine (Scr), fasting blood glucose (GLU), and uric acid (UA), negatively correlated with uACR and high-density lipoprotein cholesterol (HDL-C), but not correlated with urinary creatinine (CREA). The area under the receiver operating characteristic (ROC) curve (AUC) of miR-23a-3p for the diagnosis of DKD was 0.686 [95% confidence interval (CI): 0.599–0.773], with a sensitivity of 64.5% and a specificity of 71.2%; the AUC for differentiating NON from DKD was 0.700 (95% CI: 0.598–0.802), with a sensitivity of 61.8% and a specificity of 77.8%. Multivariate logistic regression analysis showed that serum miR-23a-3p
levels were not associated with the development of DKD after adjusting for other levels of influence and were not significant for the differentiation of NON and DKD.
Conclusion: Serum miR-23a-3p levels are decreased in T2DN patients, and this change becomes more significant with the severity of the disease, which may be a marker for the early diagnosis and progression of T2DN.
Keywords
type 2 diabetic nephropathy; proteinuria; miR-23a-3p; diagnosis
About this articleTitle
Clinical value of miR-23a-3p expression in early diagnosis of diabetic kidney disease
Journal
Issue
Article type
Original paper
Pages
414-420
Published online
2023-07-27
Page views
782
Article views/downloads
317
DOI
Pubmed
Bibliographic record
Endokrynol Pol 2023;74(4):414-420.
Keywords
type 2 diabetic nephropathy
proteinuria
miR-23a-3p
diagnosis
Authors
Xiaomei Meng
Xiao Yu
Peipei Lei
References (16)- Gross JL, de Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005; 28(1): 164–176.
- Adler AI, Stevens RJ, Manley SE, et al. UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003; 63(1): 225–232.
- American Diabetes Association. Standards of medical care in diabetes--2008. Diabetes Care. 2008; 31 Suppl 1: S12–S54.
- Ninomiya T, Perkovic V, de Galan BE, et al. ADVANCE Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009; 20(8): 1813–1821.
- Sankrityayan H, Kulkarni YA, Gaikwad AB. Diabetic nephropathy: The regulatory interplay between epigenetics and microRNAs. Pharmacol Res. 2019; 141: 574–585.
- Li Mo, Guo Q, Cai H, et al. miR-218 regulates diabetic nephropathy via targeting IKK-β and modulating NK-κB-mediated inflammation. J Cell Physiol. 2020; 235(4): 3362–3371.
- Cho HJ, Eun JW, Baek GOk, et al. Serum Exosomal MicroRNA, miR-10b-5p, as a Potential Diagnostic Biomarker for Early-Stage Hepatocellular Carcinoma. J Clin Med. 2020; 9(1).
- Han R, Li Ke, Li Li, et al. Expression of microRNA-214 and galectin-3 in peripheral blood of patients with chronic heart failure and its clinical significance. Exp Ther Med. 2020; 19(2): 1322–1328.
- Kim H, Bae YU, Jeon JS, et al. The circulating exosomal microRNAs related to albuminuria in patients with diabetic nephropathy. J Transl Med. 2019; 17(1): 236.
- Yang F, Cui Z, Deng H, et al. Identification of miRNAs-genes regulatory network in diabetic nephropathy based on bioinformatics analysis. Medicine (Baltimore). 2019; 98(27): e16225.
- Peters LJF, Floege J, Biessen EAL, et al. MicroRNAs in Chronic Kidney Disease: Four Candidates for Clinical Application. Int J Mol Sci. 2020; 21(18).
- Tayel SI, Saleh AA, El-Hefnawy SM, et al. Simultaneous Assessment of MicroRNAs 126 and 192 in Diabetic Nephropathy Patients and the Relation of these MicroRNAs with Urinary Albumin. Curr Mol Med. 2020; 20(5): 361–371.
- Kölling M, Kaucsar T, Schauerte C, et al. Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice. Mol Ther. 2017; 25(1): 165–180.
- Civantos E, Bosch E, Ramirez E, et al. Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway. Diabetes Metab Syndr Obes. 2017; 10: 207–222.
- Ma J, Wang Y, Xu HT, et al. MicroRNA: a novel biomarker and therapeutic target to combat autophagy in diabetic nephropathy. Eur Rev Med Pharmacol Sci. 2019; 23(14): 6257–6263.
- Yu J, Yu C, Feng B, et al. Intrarenal microRNA signature related to the fibrosis process in chronic kidney disease: identification and functional validation of key miRNAs. BMC Nephrol. 2019; 20(1): 336.
